Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms

JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In SET2 cells, AURKA and A...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Keli, Carlos, Jorge Antonio Elias Godoy, Alves-Paiva, Raquel de Melo, Vicari, Hugo Passos, Souza Santos, Fábio Pires de, Hamerschlak, Nelson, Costa-Lotufo, Leticia Veras, Traina, Fabiola, Machado-Neto, João Agostinho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616334/
https://www.ncbi.nlm.nih.gov/pubmed/31289316
http://dx.doi.org/10.1038/s41598-019-46163-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616334/
https://www.ncbi.nlm.nih.gov/pubmed/31289316
http://dx.doi.org/10.1038/s41598-019-46163-2

Ejemplares similares